血栓管理デバイスの世界市場：洞察、競合情勢、市場予測：2032年

血栓管理デバイスの市場規模は、2024年に18億3,879万米ドルとなりました。同市場は、2025年から2032年までの予測期間中にCAGR 4.63％で成長し、2032年には26億3,273万米ドルに達すると予測されています。心血管疾患の有病率の上昇、糖尿病や高血圧などの生活習慣病、継続的な製品革新が血栓管理デバイス市場の成長を促進しています。心血管疾患とこれらの疾患による関連リスクは、高度な血栓予防・治療技術に対する需要を増加させます。さらに、機械的血栓除去ツールやカテーテルベースのシステムなど、侵襲性が低く効果的なデバイスの新たな開発が市場開拓を後押しし、医療従事者の血栓管理を容易にしています。これらの要因が相まって、2025年から2032年までの予測期間中、血栓管理デバイスの市場全体が拡大すると予想されます。

血栓管理デバイス市場力学：

英国心臓財団（British Heart Foundation）が提供した最近のデータ（2024年）によると、世界全体で約6億2,000万人、約13人に1人が心臓・循環器疾患を抱えて生活しています。さらに、英国心臓財団（British Heart Foundation）が提供した最近のデータ（2024年）によると、冠動脈（虚血性）心疾患は世界で推定2億人が罹患しており、そのうち約1億1,000万人の男性と8,000万人の女性が罹患しています。さらに、約5,600万人の女性と4,500万人の男性が脳卒中の生存者でした。世界中で少なくとも1,300万人が先天性心疾患を患っていると推定され、さらに数百万人が診断されていない可能性があります。

心臓発作、脳卒中、末梢動脈疾患などの心血管疾患（CVD）の発生率が上昇していることは、血栓管理デバイスの市場を大幅に押し上げています。これらの疾患は血栓の形成を伴うことが多く、速やかに治療しなければ生命を脅かす合併症を引き起こす可能性があります。機械的血栓除去システムやカテーテル指示血栓溶解療法を含む血栓管理デバイスは、血栓を除去または溶解するための低侵襲な選択肢を提供し、患者の転帰を改善し、複雑な手術の必要性を減らすことで、世界中の市場成長をエスカレートさせています。

さらに、国際糖尿病連合が最近発表した最新情報によると、2021年には20～79歳の成人の約5億3,700万人が糖尿病を患っています。この数は2030年までに6億4,300万人、2045年までに7億8,300万人に増加すると予測されています。

さらに、IDF Diabetes Atlasが提供した最近のデータによると、2022年には、全世界で875万人の1型糖尿病患者のうち、152万人が20歳未満でした。さらに、2022年に新たに発症する1型糖尿病患者の62％が20歳以上の高齢者です。糖尿病は血栓形成を含む血管合併症のリスクを著しく高めるため、糖尿病有病率の上昇が血栓管理デバイスの需要を牽引しています。このリスクの上昇により、血栓除去装置、カテーテル指示血栓溶解療法、その他血栓を迅速に溶解または除去するように設計された低侵襲手技などの高度な血栓管理ソリューションが必要となり、血流を改善し合併症を減少させることで、世界中の血栓管理デバイス市場全体を押し上げています。

さらに、企業は血栓管理デバイスの生産を拡大し、新製品の承認を得ることで、市場でのプレゼンスを戦略的に拡大し、さらなる成長を促進しています。例えば、2025年3月、Imperative Care, Inc.はシンフォニーTM 16Fカテーテルの82cmバージョンの米国食品医薬品局（FDA）510（k）認可を発表しました。このカテーテルは、静脈血栓症患者のケアを向上させるために設計された同社の最新のイノベーションであり、静脈血栓症は脚や腹部の静脈に形成される血栓によって引き起こされ、放置すると生命を脅かす深刻な疾患です。

しかし、製品リコールの増加や、出血、血管損傷、感染など血栓管理デバイスに関連する合併症のリスクが、血栓管理デバイスの今後の市場を阻害する可能性があります。

血栓管理デバイス市場セグメント分析：

血栓管理市場の製品タイプ別では、ステントリトリーバーのカテゴリーが2024年に最大のシェアを占めると予想されています。これは、ステントリトリーバーを用いた機械的血栓除去術が、急性脳卒中患者において内科的治療のみと比較して優れた臨床転帰をもたらすことが報告されているなどの利点があるためと考えられます。それに加えて、ステントリトリーバーは全身的血栓溶解療法と同様の安全性プロファイルを有しています。これらのデバイスは、脳の閉塞動脈から血栓を機械的に除去するように設計されており、それによって、長期的な神経障害を予防するための重要な時間内に、迅速かつ効果的に血流を回復させることができます。

さらに、視認性を向上させるためにプラチナを組み込んだり（Trevo ProvueおよびSolitaire Platinum）、長さを40mmまで伸ばしたりするなどの製品設計の改良が、ファーストパス再灌流の成績向上に役立っています。回収可能な自己拡張型血栓除去デバイスの登場はさらに、デバイスが直ちに血流を回復させ、恒久的なステントの留置を回避し、血液を直ちに回復させ、恒久的なステントの留置の必要性をなくし、それによってステント内再狭窄の可能性を減少させるなどの利点を提供します。ステントリトリーバーは、従来の血栓溶解薬単独療法と比較して、高い再疎通率、機能回復の改善、死亡率の低下など、優れた治療成績をもたらします。このため、主要な脳卒中治療ガイドラインに組み込まれ、世界中の病院や脳卒中センターでの採用が加速しています。さらに、ステントリトリーバーの橈骨方向への力が強化され、血栓の統合性が向上し、ナビゲーション性が改善された次世代ステントリトリーバーなどの技術革新により、ステントリトリーバーの臨床的有用性はさらに拡大しています。

さらに、新製品の発売も予測期間中に世界のステントリトリーバー市場を急増させる可能性が高いです。例えば、2024年8月、Gravity Medical Technologyは、次世代脳卒中治療デバイスであるニュートロン吸引カテーテルとSupernovaステントリトリーバーの発売を発表しました。Supernovaステントリトリーバーの革新的なデザインは、非白人集団に多く見られる傾向のある、フィブリンに富む硬い（白い）血栓の捕捉と除去を強化します。

したがって、上記の要因により、ステントリトリーバーのカテゴリーはかなりの収益を生み出し、予測期間中に世界の血栓管理デバイス市場全体の成長を押し上げると予想されます。

北米は、2024年の血栓管理デバイス市場で、全地域の中で最も高い割合を占めると予想されています。肥満、高血圧、糖尿病の有病率上昇によるDVT、塞栓症の有病率上昇、高齢化、がんの有病率上昇、疾患治療に対する認識に関する政府のイニシアティブの高まりなど、主要な成長要因の重要性により、北米の血栓管理デバイス市場は予測期間中にプラス成長を遂げると予想されます。

米国疾病予防管理センター（Centers for Disease Control and Prevention）の最新データ（2024年）によると、2022年には成人の約4.9％が冠動脈性心疾患と診断されました。さらに、2023年までに米国では推定1,210万人が心房細動に罹患すると予測されました。さらに、米国では毎年79万5,000人以上が脳卒中を経験しており、そのうち約61万人が初めての脳卒中です。注目すべきは、これらの脳卒中のうち18万5,000人近く、つまり約4人に1人が以前に脳卒中を起こしたことがある人であることです。

冠動脈性心疾患（CHD）の有病率の上昇は、血栓管理デバイスの市場を大幅に押し上げます。CHDでは冠動脈に血栓が形成されることが多いため、血流を回復させて心臓発作を予防する効果的な治療に対する需要が高まっています。血栓除去装置や塞栓システムなどの血栓管理デバイスは、このような症状の管理に不可欠であり、病院や救急医療現場での採用を促進しています。

さらに、米国疾病予防管理センター（Centre for Disease Control and Prevention）が提供した最新の報告書（2024年）によると、推計では全年齢で3,840万人（米国人口の11.6％）が糖尿病を患っています。また、18歳以上の糖尿病患者は3,810万人で、米国成人の14.7％を占めています。糖尿病はしばしば末梢動脈疾患や深部静脈血栓症などの合併症を引き起こし、血栓が血管を塞いで血行を悪くします。糖尿病患者の効果的な血栓予防と治療に対するニーズの高まりは、病院と外来患者の両方における血栓摘出術とカテーテルシステムを含む血栓管理デバイスの採用を後押しし、地域全体の市場を拡大しています。

さらに、米国の血栓管理デバイス市場の成長にプラスの影響を与えている主な理由の1つは、米国人口におけるがんの有病率の上昇です。GLOBOCANが提供した最新データによると、2022年に北米で新たに発生したがん患者は267万人と推定され、2045年には383万人に増加すると予測されています。がん患者は、血栓形成の可能性を高める特定の異常凝固因子を持っていると考えられています。さらに、化学療法は深部静脈血栓症の原因となる静脈血栓症のリスク増加にも関係しています。従って、同国におけるがんの有病率の上昇は、血栓管理デバイスに対するニーズの増加を助け、製品需要の増加と北米の血栓管理デバイス市場の成長を助けると予想されます。

加えて、主要市場参入企業による戦略的活動の活発化も、予測期間中に同地域全体の血栓管理デバイス市場を急増させる可能性が高いです。例えば、2023年6月、世界的ヘルスケア企業であるPenumbra, Inc.は、FDAの認可を取得し、高度な動脈血栓除去システムであるLightning Bolt（TM）7を発売しました。この装置は、Lightning Intelligent Aspirationテクノロジーとマイクロプロセッサ・アルゴリズムを組み合わせることにより、調節された吸引を導入しました。この装置は、急性四肢虚血（ALI）、冬眠血栓、内臓閉塞などの病態をターゲットに、出血を最小限に抑えながら、繊維性の大きな動脈血栓を迅速に除去するように設計されました。

したがって、上記の要因は予測期間中に北米の血栓管理デバイス市場の成長を促進すると予想されます。

血栓管理デバイス市場の主要参入企業

血栓管理デバイス市場で事業を展開する主要市場参入企業には、Edward LifeSciences Corporation、Stryker、Medical Device Business Services, Inc.、Medtronic PLC、Penumbra、Microvention Inc.、Terumo Corporation、Boston Scientific Inc.、Abbott、Acandis GmbH、Perflow Medical Ltd.、Koninklijke Philips N.V.、phenox GmbH、AngioDynamics、ARGON MEDICAL、BD、B. Braun Melsungen AG、Cardinal Health.、Braile Biomedica、Cookなどがあります。

血栓管理デバイス市場における最近の開発活動：

• 2024年4月、Penumbra Inc.がLightning Flash 2.0を発売-血栓を迅速に除去する最新のCAVT技術
• 2024年2月、Johnson & Johnson MedTech傘下のCERENOVUS, Inc.は、急性虚血性脳卒中患者の血行再建術用に設計されたCEREGLIDE（TM）71 Intermediate Catheterの発売を発表しました。この次世代カテーテルはCEREGLIDEファミリーの一部であり、EMBOTRAP（TM）III血行再建デバイスのようなステントリトリーバーを神経血管系に直接吸引・送達するために最適化されました。

血栓管理デバイス市場レポート調査の主なポイント

• 現在の血栓管理デバイスの市場規模分析（2024年）、8年間（2025年～2032年）の市場予測
• 過去3年間に起こった主な製品/技術開発、合併、買収、提携、合弁事業
• 血栓管理デバイス市場を独占する主要企業
• 血栓管理デバイス市場において競合他社が利用できる様々な機会
• 2024年に上位を占めるセグメントと2032年におけるこれらのセグメントの業績
• 現在の血栓管理デバイス市場のシナリオにおいて、上位の業績を上げている地域や国
• 今後、企業が血栓管理デバイス市場成長の機会に集中すべき地域や国

血栓管理デバイス市場のよくある質問

1.血栓管理デバイス

• 血栓管理デバイスとは、末梢血管や神経血管から血栓を除去するための医療機器です。

2.血栓管理デバイス市場

• 血栓管理デバイス市場は、2024年に18億3,879万米ドルと評価され、2025年から2032年までの予測期間中にCAGR 4.63%で成長し、2032年には26億3,273万米ドルに達します。

3.血栓管理デバイス市場の促進要因

• 心血管疾患の有病率の上昇、糖尿病や高血圧などの生活習慣病、継続的な製品革新が血栓管理デバイス市場の成長を促進しています。心血管疾患とこれらの疾患別関連リスクは、高度な血栓予防・治療技術に対する需要を増加させます。さらに、機械的血栓除去ツールやカテーテルベースのシステムなど、侵襲性が低く効果的なデバイスの新たな開発が市場開拓を後押しし、医療従事者の血栓管理を容易にしています。これらの要因が相まって、2025年から2032年までの予測期間中、血栓管理デバイスの市場全体が拡大すると予想されます。

4.血栓管理デバイス市場で事業を展開する主要参入企業

• 血栓管理デバイス市場で事業を展開している主要な市場参入企業には、Edward LifeSciences Corporation、Stryker、Medical Device Business Services, Inc.、Medtronic PLC、Penumbra、Microvention Inc.、Terumo Corporation、Boston Scientific Inc.、Abbott、Acandis GmbH、Perflow Medical Ltd.、Koninklijke Philips N.V.、phenox GmbH、AngioDynamics、ARGON MEDICAL、BD、B. Braun Melsungen AG、Cardinal Health、Braile Biomedica、Cookなどがあります。

5.血栓管理デバイス市場で最もシェアが高い地域

• 北米は、2024年の血栓管理デバイス市場で、全地域の中で最も高い割合を占めると予想されています。肥満、高血圧、糖尿病の有病率増加別DVT、塞栓症の有病率上昇、高齢化、がんの有病率増加、疾患治療に対する認識に関する政府のイニシアチブの高まりといった主要成長要因の重要性により、北米の血栓管理デバイス市場は予測期間中にプラス成長を遂げると予想されます。

目次

第1章 血栓管理デバイス市場レポートのイントロダクション

第2章 血栓管理デバイス市場のエグゼクティブサマリー

第3章 競合情勢

第4章 規制分析

• 米国
• 欧州
• 日本
• 中国

第5章 血栓管理デバイス市場の主な要因分析

• 血栓管理デバイス市場促進要因
  • 心血管疾患の罹患率の上昇
  • 糖尿病や高血圧などの生活習慣病の増加
  • 世界中で製品開発活動が活発化
• 血栓管理デバイス市場抑制要因と課題
  • 製品リコール件数の増加
  • デバイスに関連する合併症のリスク
• 血栓管理デバイスの市場機会
  • 人工知能の統合

第6章 血栓管理デバイス市場：ポーターのファイブフォース分析

第7章 血栓管理デバイス市場評価

• 製品タイプ別
  • 血栓除去デバイス
  • 塞栓切開カテーテル
  • 下大静脈フィルター
  • 圧縮衣類
  • その他
• エンドユーザー別
  • 病院
  • 外来手術センター
  • 在宅ケア
• 地域別
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 血栓管理デバイス市場の企業と製品プロファイル

• Edward LifeSciences Corporation
• Stryker
• Medical Device Business Services, Inc.
• Medtronic PLC
• Penumbra
• Microvention Inc.
• Terumo Corporation
• Boston Scientific Inc.
• Abbott
• Acandis GmbH
• Perflow Medical Ltd.
• Koninklijke Philips N.V.
• phenox GmbH
• AngioDynamics
• ARGON MEDICAL
• BD
• B. Braun Melsungen AG
• Cardinal Health
• Braile Biomedica Cook

第9章 KOLの見解

第10章 プロジェクトアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Clot Management Devices Market in Global (2022-2032)
• Table 3: Clot Management Devices Market in Global by Product Type (2022-2032)
• Table 4: Clot Management Devices Market in Global by End-User (2022-2032)
• Table 5: Clot Management Devices Market in Global by Geography (2022-2032)
• Table 6: Clot Management Devices Market in North America (2022-2032)
• Table 7: Clot Management Devices Market in the United States (2022-2032)
• Table 8: Clot Management Devices Market in Canada (2022-2032)
• Table 9: Clot Management Devices Market in Mexico (2022-2032)
• Table 10: Clot Management Devices Market in Europe (2022-2032)
• Table 11: Clot Management Devices Market in France (2022-2032)
• Table 12: Clot Management Devices Market in Germany (2022-2032)
• Table 13: Clot Management Devices Market in United Kingdom (2022-2032)
• Table 14: Clot Management Devices Market in Italy (2022-2032)
• Table 15: Clot Management Devices Market in Spain (2022-2032)
• Table 16: Clot Management Devices Market in the Rest of Europe (2022-2032)
• Table 17: Clot Management Devices Market in Asia-Pacific (2022-2032)
• Table 18: Clot Management Devices Market in China (2022-2032)
• Table 19: Clot Management Devices Market in Japan (2022-2032)
• Table 20: Clot Management Devices Market in India (2022-2032)
• Table 21: Clot Management Devices Market in Australia (2022-2032)
• Table 22: Clot Management Devices Market in South Korea (2022-2032)
• Table 23: Clot Management Devices Market in Rest of Asia-Pacific (2022-2032)
• Table 24: Clot Management Devices Market in the Rest of the World (2022-2032)
• Table 25: Clot Management Devices Market in the Middle East (2022-2032)
• Table 26: Clot Management Devices Market in Africa (2022-2032)
• Table 27: Clot Management Devices Market in South America (2022-2032)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Clot Management Devices Market in Global (2022-2032)
• Figure 3: Clot Management Devices Market in Global by Product Type (2022-2032)
• Figure 4: Clot Management Devices Market in Global by End-User (2022-2032)
• Figure 5: Clot Management Devices Market in Global by Geography (2022-2032)
• Figure 6: Clot Management Devices Market in North America (2022-2032)
• Figure 7: Clot Management Devices Market in the United States (2022-2032)
• Figure 8: Clot Management Devices Market in Canada (2022-2032)
• Figure 9: Clot Management Devices Market in Mexico (2022-2032)
• Figure 10: Clot Management Devices Market in Europe (2022-2032)
• Figure 11: Clot Management Devices Market in France (2022-2032)
• Figure 12: Clot Management Devices Market in Germany (2022-2032)
• Figure 13: Clot Management Devices Market in United Kingdom (2022-2032)
• Figure 14: Clot Management Devices Market in Italy (2022-2032)
• Figure 15: Clot Management Devices Market in Spain (2022-2032)
• Figure 16: Clot Management Devices Market in the Rest of Europe (2022-2032)
• Figure 17: Clot Management Devices Market in Asia-Pacific (2022-2032)
• Figure 18: Clot Management Devices Market in China (2022-2032)
• Figure 19: Clot Management Devices Market in Japan (2022-2032)
• Figure 20: Clot Management Devices Market in India (2022-2032)
• Figure 21: Clot Management Devices Market in Australia (2022-2032)
• Figure 22: Clot Management Devices Market in South Korea (2022-2032)
• Figure 23: Clot Management Devices Market in Rest of Asia-Pacific (2022-2032)
• Figure 24: Clot Management Devices Market in the Rest of the World (2022-2032)
• Figure 25: Clot Management Devices Market in the Middle East (2022-2032)
• Figure 26: Clot Management Devices Market in Africa (2022-2032)
• Figure 27: Clot Management Devices Market in South America (2022-2032)
• Figure 28: Market Drivers
• Figure 29: Market Barriers
• Figure 30: Market Opportunities
• Figure 31: PORTER'S Five Force Analysis

Clot Management Devices by Product Type (Thrombectomy Devices [Catheter-Directed Thrombolysis Devices, Aspiration Devices, and Stent Retrievers], Embelecotomy Catheters, Inferior Vena Cava Filters [Retrievable and Permanent], Compression Garments, and Others), End User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising prevalence of cardiovascular diseases, increasing prevalence of lifestyle disorders such as diabetes and hypertension, and increased in product developmental activities across the globe.

The clot management devices market was valued at USD 1,838.79 million in 2024, growing at a CAGR of 4.63% during the forecast period from 2025 to 2032 to reach USD 2,632.73 million by 2032. The rising prevalence of cardiovascular diseases, lifestyle disorders like diabetes and hypertension, and ongoing product innovation are driving the growth of the clot management devices market. Cardiovascular conditions and related risks from these disorders increase demand for advanced clot prevention and treatment technologies. Additionally, new developments in less invasive and more effective devices, such as mechanical thrombectomy tools and catheter-based systems, are boosting market expansion, making it easier for healthcare providers to manage blood clots. Together, these factors are expected to boost the overall market for clot management devices during the forecast period from 2025 to 2032.

Clot Management Devices Market Dynamics:

According to recent data provided by the British Heart Foundation (2024), globally, approximately 620 million people, or about 1 in 13 individuals, live with heart and circulatory diseases. Furthermore, as per the recent data provided by the British Heart Foundation (2024), coronary (ischemic) heart disease, affected an estimated 200 million people globally in which approximately 110 million men and 80 million women were affected. Additionally, around 56 million women and 45 million men were stroke survivors. It was estimated that at least 13 million people worldwide lived with congenital heart disease, with potentially millions more undiagnosed.

The rising incidence of cardiovascular diseases (CVDs), such as heart attacks, strokes, and peripheral artery disease, significantly boosts the market for clot management devices. These conditions are often associated with the formation of blood clots, which can lead to life-threatening complications if not treated promptly. Clot management devices, including mechanical thrombectomy systems and catheter-directed thrombolysis, provide minimally invasive options for removing or dissolving clots, improving patient outcomes and reducing the need for complex surgeries thereby escalating the market growth across the globe.

Additionally, according to the recent update provided by the International Diabetes Federation, in 2021, approximately 537 million adults aged 20-79 were living with diabetes. This number was projected to rise to 643 million by 2030 and 783 million by 2045.

Additionally, as per the recent data provided by the IDF Diabetes Atlas, in 2022, out of the 8.75 million people living with type 1 diabetes worldwide, 1.52 million were under 20 years old. Additionally, 62% of all new type 1 diabetes cases in 2022 occurred in people aged 20 years or older. The increasing prevalence of diabetes is driving the demand for clot management devices, as diabetes significantly raises the risk of vascular complications, including blood clot formation. This elevated risk necessitates advanced clot management solutions such as thrombectomy devices, catheter-directed thrombolysis, and other minimally invasive procedures designed to quickly dissolve or remove clots, improving blood flow and reducing complications and thereby boosting the overall market of clot management devices across the globe.

Additionally, companies are amplifying their production of clot management devices and gaining approvals for the new products, thereby strategically expanding their market presence and driving further growth. For instance, in March 2025, Imperative Care, Inc. announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the 82cm version of its SymphonyTM 16F Catheter, the company's latest innovation designed to elevate care for patients with venous thrombosis, a serious condition caused by a blood clot forming in the veins of the legs or abdomen that can have a life-threatening impact if left untreated.

However, the increased number of product recalls and the risk of complications associated with clot management devices such as bleeding, vessel damage, or infection may hinder the future market of clot management devices.

Clot Management Devices Market Segment Analysis:

Clot Management Devices by Product Type (Thrombectomy Devices [Catheter-Directed Thrombolysis Devices, Aspiration Devices, and Stent Retrievers], Embelecotomy Catheters, Inferior Vena Cava Filters [Retrievable and Permanent], Compression Garments, and Others), End User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the clot management market, the stent retrievers category is expected to hold the largest share in the year 2024. This can be ascribed to their advantages such as mechanical thrombectomy with stent retrievers is reported to produce superior clinical outcomes in acute stroke patients compared to medical therapy alone. In addition to that, stent retrievers have a safety profile similar to that of systemic thrombolytic therapy. These devices are designed to mechanically remove blood clots from blocked arteries in the brain, thereby restoring blood flow quickly and effectively often within the critical window for preventing long-term neurological damage.

Moreover, improvements in product design such as the incorporation of platinum for improved visibility (Trevo Provue and Solitaire Platinum) and longer lengths up to 40 mm have helped in improving the first-pass reperfusion outcomes. The entry of recoverable self-expanding thrombectomy devices further offers advantages such as the devices restore flow immediately and avoid the placement of a permanent stent, immediate restoration of blood, and eliminating the need for the placement of a permanent stent thereby reducing the chances of in-stent restenosis. Stent retrievers offer superior outcomes compared to traditional thrombolytic drug therapy alone, including higher rates of recanalization, improved functional recovery, and reduced mortality. This has led to their inclusion in major stroke treatment guidelines and accelerated adoption across hospitals and stroke centers globally. Furthermore, technological innovations such as next-generation stent retrievers with enhanced radial force, better clot integration, and improved navigability are further expanding their clinical utility.

In addition, new product launches are also likely to upsurge the global stent retrievers market during the forecasted period. For instance, in August 2024, Gravity Medical Technology announced the launch of its next-generation stroke treatment devices the Neutron aspiration catheter and the Supernova stent retriever. The Supernova stent retriever's innovative design enhances the capture and removal of hard fibrin-rich (white) clots, which tend to present more in non-Caucasian populations.

Therefore, owing to the above-mentioned factors, the stent retriever's category is expected to generate considerable revenue thereby pushing the overall growth of the global clot management devices market during the forecast period.

North America is expected to dominate the overall clot management devices market:

North America is expected to account for the highest proportion of the clot management devices market in 2024, out of all regions. Owing to the significance of key growth factors such as the rising prevalence of DVT, embolism due to the increasing prevalence of obesity, hypertension, and diabetes, the aging population, the growing prevalence of cancers, and rising government initiatives regarding disease treatment awareness, the North America clot management devices market is expected to witness positive growth during the forecast period.

According, to recent data from the Centers for Disease Control and Prevention (2024), in 2022, approximately 4.9% of adults were diagnosed with coronary heart disease. Furthermore, by 2023, an estimated 12.1 million individuals in the United States were projected to have atrial fibrillation. Additionally, each year, over 795,000 people in the U.S. experience a stroke, with around 610,000 of these being first-time strokes. Notably, nearly 185,000 of these strokes, or about one in four, occur in individuals who have previously had a stroke.

The rising prevalence of coronary heart disease (CHD) significantly boosts the market for clot management devices. As CHD often leads to the formation of blood clots in coronary arteries, there is an increased demand for effective treatments to restore blood flow and prevent heart attacks. Clot management devices, such as thrombectomy and embolization systems, are essential in managing these conditions, driving their adoption in hospitals and emergency care settings.

Additionally, according to the latest report provided by the Centre for Disease Control and Prevention (2024), estimates indicated that 38.4 million people of all ages, or 11.6% of the U.S. population, had diabetes. Additionally, approximately, 38.1 million individuals aged 18 years and older, representing 14.7% of all U.S. adults, were affected by diabetes. Diabetes often leads to complications such as peripheral artery disease and deep vein thrombosis, where blood clots can block vessels and impair circulation. This rising need for effective clot prevention and treatment in diabetic populations is boosting the adoption of clot management devices, including thrombectomy and catheter systems, in both hospital and outpatient settings thereby escalating the overall market across the region.

Furthermore, one of the key reasons positively influencing the growth of the United States clot management devices market is the rising prevalence of cancers in the US population. As per the latest data provided by GLOBOCAN, in 2022, the estimated new cases of cancer in North America was 2.67 million and the projections were subjected to an increase of 3.83 million by 2045. Cancer patients are thought to have specific abnormal coagulation factors which increase the chances of thrombus formation. Additionally, chemotherapy is also related to the increased risk of venous thrombosis resulting in deep vein thrombosis. Therefore, the rising prevalence of cancers in the country is expected to aid in the growing need for thrombus management devices thereby resulting in an increase in product demand and aiding in the growth of the North America clot management devices market.

In addition, the increased strategic activities by the key market players are also likely to upsurge the clot management devices market across the region during the forecasted period. For instance, in June 2023, Penumbra, Inc., a global healthcare company, received FDA clearance and launched Lightning Bolt(TM) 7, an advanced arterial thrombectomy system. The device introduced modulated aspiration by combining Lightning Intelligent Aspiration technology with a microprocessor algorithm. It was designed to quickly remove large, fibrous arterial clots with minimal blood loss, targeting conditions like acute limb ischemia (ALI), hibernating thrombus, and visceral occlusions.

Therefore, the above-mentioned factors are expected to bolster the growth of the clot management devices market in North America during the forecast period.

Clot Management Devices Market Key Players:

Some of the key market players operating in the clot management devices market include Edward LifeSciences Corporation, Stryker, Medical Device Business Services, Inc., Medtronic PLC, Penumbra, Microvention Inc., Terumo Corporation, Boston Scientific Inc, Abbott, Acandis GmbH, Perflow Medical Ltd., Koninklijke Philips N.V., phenox GmbH, AngioDynamics, ARGON MEDICAL, BD, B. Braun Melsungen AG, Cardinal Health., Braile Biomedica, Cook, and others.

Recent Developmental Activities in the Clot Management Devices Market:

• In April 2024, Penumbra Inc. launched Lightning Flash 2.0 - the latest CAVT technology designed to rapidly remove blood clots
• In February 2024, CERENOVUS, Inc., part of Johnson & Johnson MedTech, announced the launch of the CEREGLIDE(TM) 71 Intermediate Catheter, designed for revascularization in acute ischemic stroke patients. This next-generation catheter, part of the CEREGLIDE family, was optimized for direct aspiration and delivering stent retrievers like the EMBOTRAP(TM) III Revascularization Device into the neurovasculature.

Key takeaways from the clot management devices market report study:

• Market size analysis for current clot management devices size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the clot management devices market.
• Various opportunities available for the other competitors in the clot management devices market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current clot management devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for clot management devices market growth in the coming future?

Target audience who can benefit from this clot management devices market report study:

• Clot management devices product providers
• Research organizations and consulting companies
• Clot management devices-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in clot management devices
• Various end-users who want to know more about the clot management devices market and the latest technological developments in the clot management devices market.

Frequently Asked Questions for the Clot Management Devices Market:

1. What are clot management devices?

• Clot management devices are medical devices that are employed in the removal of blood clots from peripheral as well as neurovasculature.

2. What is the market for clot management devices?

• The clot management devices market was valued at USD 1,838.79 million in 2024, growing at a CAGR of 4.63% during the forecast period from 2025 to 2032 to reach USD 2,632.73 million by 2032.

3. What are the drivers for the clot management devices market?

• The rising prevalence of cardiovascular diseases, lifestyle disorders like diabetes and hypertension, and ongoing product innovation are driving the growth of the clot management devices market. Cardiovascular conditions and related risks from these disorders increase demand for advanced clot prevention and treatment technologies. Additionally, new developments in less invasive and more effective devices, such as mechanical thrombectomy tools and catheter-based systems, are boosting market expansion, making it easier for healthcare providers to manage blood clots. Together, these factors are expected to boost the overall market for clot management devices during the forecast period from 2025 to 2032.

4. Who are the key players operating in the clot management devices market?

• Some of the key market players operating in the clot management devices market include Edward LifeSciences Corporation, Stryker, Medical Device Business Services, Inc., Medtronic PLC, Penumbra, Microvention Inc., Terumo Corporation, Boston Scientific Inc, Abbott, Acandis GmbH, Perflow Medical Ltd., Koninklijke Philips N.V., phenox GmbH, AngioDynamics, ARGON MEDICAL, BD, B. Braun Melsungen AG, Cardinal Health., Braile Biomedica, Cook, and others.

5. Which region has the highest share in the clot management devices market?

• North America is expected to account for the highest proportion of the clot management devices market in 2024, out of all regions. Owing to the significance of key growth factors such as the rising prevalence of DVT, embolism due to the increasing prevalence of obesity, hypertension, and diabetes, the aging population, the growing prevalence of cancers, and rising government initiatives regarding disease treatment awareness, the North America clot management devices market is expected to witness positive growth during the forecast period.

Table of Contents

1. Clot Management Devices Market Report Introduction

• 1.1 Scope of the Study
• 1.2 Market Segmentation
• 1.3 Market Assumption

2. Clot Management Devices Market Executive Summary

• 2.1 Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1 The United States
• 4.2 Europe
• 4.3 Japan
• 4.4 China

5. Clot Management Devices Market Key Factors Analysis

• 5.1. Clot Management Devices Market Drivers
  • 5.1.1 The rising prevalence of cardiovascular diseases
  • 5.1.2 Increasing prevalence of lifestyle disorders such as diabetes and hypertension
  • 5.1.3 Increased product developmental activities across the globe.
• 5.2 Clot Management Devices Market Restraints and Challenges
  • 5.2.1 Increased number of product recalls
  • 5.2.2 The risk of complications associated with the devices
• 5.3 Clot Management Devices Market Opportunities
  • 5.3.1 Integration of artificial intelligence

6. Clot Management Devices Market Porter's Five Forces Analysis

• 6.1 Bargaining Power of Suppliers
• 6.2 Bargaining Power of Consumers
• 6.3 Threat of New Entrants
• 6.4 Threat of Substitutes
• 6.5 Competitive Rivalry

7. Clot Management Devices Market Assessment

• 7.1 By Product Type
  • 7.1.1 Thrombectomy Devices
    • 7.1.1.1 Catheter-Directed Thrombolysis Devices
    • 7.1.1.2 Aspiration Devices
    • 7.1.1.3 Stent Retrievers
  • 7.1.2 Embelecotomy Catheters
  • 7.1.3 Inferior Vena Cava Filters
    • 7.1.3.1 Retrievable
    • 7.1.3.2 Permanent
  • 7.1.4 Compression Garments
  • 7.1.5 Others
• 7.2 By End-Users
  • 7.2.1 Hospitals
  • 7.2.2 Ambulatory Surgical Centers
  • 7.2.3 Homecare Settings
  • 7.2.4 Others
• 7.3 By Geography
  • 7.3.1 North America
    • 7.3.1.1 United States Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.1.2 Canada Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.1.3 Mexico Clot Management Devices Market Size in USD million (2022-2032)
  • 7.3.2 Europe
    • 7.3.2.1 France Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.2.2 Germany Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.2.3 United Kingdom Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.2.4 Italy Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.2.5 Spain Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.2.6 Rest of Europe Clot Management Devices Market Size in USD million (2022-2032)
  • 7.3.3 Asia-Pacific
    • 7.3.3.1 China Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.3.2 Japan Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.3.3 India Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.3.4 Australia Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.3.5 South Korea Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.3.6 Rest of Asia-Pacific Clot Management Devices Market Size in USD million (2022-2032)
  • 7.3.4 Rest of the World (RoW)
    • 7.3.4.1 Middle East Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.4.2 Africa Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.4.3 South America Clot Management Devices Market Size in USD million (2022-2032)

8. Clot Management Devices Market Company and Product Profiles

• 8.1 Edward LifeSciences Corporation
  • 8.1.1 Company Overview
  • 8.1.2 Company Snapshot
  • 8.1.3 Financial Overview
  • 8.1.4 Product Listing
  • 8.1.5 Entropy
• 8.2 Stryker
  • 8.2.1 Company Overview
  • 8.2.2 Company Snapshot
  • 8.2.3 Financial Overview
  • 8.2.4 Product Listing
  • 8.2.5 Entropy
• 8.3 Medical Device Business Services, Inc.
  • 8.3.1 Company Overview
  • 8.3.2 Company Snapshot
  • 8.3.3 Financial Overview
  • 8.3.4 Product Listing
  • 8.3.5 Entropy
• 8.4 Medtronic PLC
  • 8.4.1 Company Overview
  • 8.4.2 Company Snapshot
  • 8.4.3 Financial Overview
  • 8.4.4 Product Listing
  • 8.4.5 Entropy
• 8.5 Penumbra
  • 8.5.1 Company Overview
  • 8.5.2 Company Snapshot
  • 8.5.3 Financial Overview
  • 8.5.4 Product Listing
  • 8.5.5 Entropy
• 8.6 Microvention Inc.
  • 8.6.1 Company Overview
  • 8.6.2 Company Snapshot
  • 8.6.3 Financial Overview
  • 8.6.4 Product Listing
  • 8.6.5 Entropy
• 8.7 Terumo Corporation
  • 8.7.1 Company Overview
  • 8.7.2 Company Snapshot
  • 8.7.3 Financial Overview
  • 8.7.4 Product Listing
  • 8.7.5 Entropy
• 8.8 Boston Scientific Inc.
  • 8.8.1 Company Overview
  • 8.8.2 Company Snapshot
  • 8.8.3 Financial Overview
  • 8.8.4 Product Listing
  • 8.8.5 Entropy
• 8.9 Abbott
  • 8.9.1 Company Overview
  • 8.9.2 Company Snapshot
  • 8.9.3 Financial Overview
  • 8.9.4 Product Listing
  • 8.9.5 Entropy
• 8.10. Acandis GmbH
  • 8.10.1 Company Overview
  • 8.10.2 Company Snapshot
  • 8.10.3 Financial Overview
  • 8.10.4 Product Listing
  • 8.10.5 Entropy
• 8.11. Perflow Medical Ltd.
  • 8.11.1 Company Overview
  • 8.11.2 Company Snapshot
  • 8.11.3 Financial Overview
  • 8.11.4 Product Listing
  • 8.11.5 Entropy
• 8.12. Koninklijke Philips N.V.
  • 8.12.1 Company Overview
  • 8.12.2 Company Snapshot
  • 8.12.3 Financial Overview
  • 8.12.4 Product Listing
  • 8.12.5 Entropy
• 8.13. phenox GmbH
  • 8.13.1 Company Overview
  • 8.13.2 Company Snapshot
  • 8.13.3 Financial Overview
  • 8.13.4 Product Listing
  • 8.13.5 Entropy
• 8.14. AngioDynamics
  • 8.14.1 Company Overview
  • 8.14.2 Company Snapshot
  • 8.14.3 Financial Overview
  • 8.14.4 Product Listing
  • 8.14.5 Entropy
• 8.15. ARGON MEDICAL
  • 8.15.1 Company Overview
  • 8.15.2 Company Snapshot
  • 8.15.3 Financial Overview
  • 8.15.4 Product Listing
  • 8.15.5 Entropy
• 8.16. BD
  • 8.16.1 Company Overview
  • 8.16.2 Company Snapshot
  • 8.16.3 Financial Overview
  • 8.16.4 Product Listing
  • 8.16.5 Entropy
• 8.17. B. Braun Melsungen AG
  • 8.17.1 Company Overview
  • 8.17.2 Company Snapshot
  • 8.17.3 Financial Overview
  • 8.17.4 Product Listing
  • 8.17.5 Entropy
• 8.18. Cardinal Health
  • 8.18.1 Company Overview
  • 8.18.2 Company Snapshot
  • 8.18.3 Financial Overview
  • 8.18.4 Product Listing
  • 8.18.5 Entropy
• 8.19. Braile Biomedica
  • 8.19.1 Company Overview
  • 8.19.2 Company Snapshot
  • 8.19.3 Financial Overview
  • 8.19.4 Product Listing
  • 8.19.5 Entropy
• 8.20. Cook
  • 8.20.1 Company Overview
  • 8.20.2 Company Snapshot
  • 8.20.3 Financial Overview
  • 8.20.4 Product Listing
  • 8.20.5 Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us